Experts Gather for International Breast Cancer Research Conference

Breast cancer specialists from all over the world head to Texas this week for the annual San Antonio Breast Cancer Symposium (SABCS). Now in its 38th year, the conference showcases the latest in breast cancer research. The event, which runs from December 8th through the 12th, is co-sponsored by the Cancer Therapy and Research Center at the University of Texas Health Science Center at San Antonio, the American Association for Cancer Research (AACR), and the Baylor College of Medicine. Get the headlines from the conference from our content partners at CURE.  December 13, 2015Kadcyla Extends Survival in Heavily Pretreated Patients With HER2+ Breast CancerDecember 11, 2015Next-Generation Drug Challenging Imbruvica in CLLDecember 10, 2015Small Study Shows Immunotherapy Effective in Metastatic Breast Cancer SubsetXgeva Generates Survival Benefit in Postmenopausal Women With Breast Cancer
Source: American Cancer Society :: News and Features - Category: Cancer & Oncology Tags: Breast Cancer Source Type: news

Related Links:

Contributors : Jacob Turner ; Xuan Wang ; Derek Blankenship ; Joyce O ’ShaughnessySeries Type : Expression profiling by arrayOrganism : Homo sapiensInflammation affects tumor immune surveillance and resistance to therapy.  Here we show that production of interleukin (IL)-1b in primary breast cancer (BC) tumors is linked with advanced disease. Patients with metastatic HER2-negative BC display a transcriptional signature of inflammation in the blood, which is attenuated after IL1 blockade.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
This article reviews the clinically most relevant presentations at the San Antonio Breast Cancer Symposium (SABCS) 2017 on the topics lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis.In a  retrospective analysis of the Women’s Health Initiative Observational Study, a reduction in the body mass index (BMI) of at least 5% within 3 years significantly reduced the risk of breast cancer compared to women with a stable weight (HR 0.77; 95% CI 0.78–0.98). In the MONALEESA-7 trial in vestigating ribociclib or placebo in combination with endocrine therapy ...
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Breast Cancer Intervention:   Drug: Capecitabine Sponsor:   Zhejiang Cancer Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Metastatic Breast Cancer Intervention:   Drug: Eribulin Sponsors:   Institut Paoli-Calmettes;   Eisai Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Le D, Gelmon KA Abstract Introduction Germline BRCA mutations (gBRCAm) are diagnosed in approximately 5% of unselected breast cancer patients. Olaparib is a new treatment option for patients with a gBRCAm who have metastatic HER2-negative breast cancer. Areas Covered Olaparib is an oral poly (ADP-ribose) polymerase inhibitor that has been shown in phase I-III clinical trials to have single-agent efficacy in breast cancer patients with gBRCAm. The recent phase III OlympiAD study demonstrated a statistically significant progression free survival benefit compared to the chemotherapy control arm, although an o...
Source: Expert Review of Clinical Pharmacology - Category: Drugs & Pharmacology Tags: Expert Rev Clin Pharmacol Source Type: research
Conclusions: In our experience, the use of odx was concordant with published recommendations and had a positive cost impact. PMID: 30111977 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Conclusions: Study results indicate that, for patients and caregivers, pd health states are associated with a deterioration of qol and utility and a decrease in productivity in both 1l and ≥2l. PMID: 30111973 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Basal/human epidermal growth factor receptor (HER)2-positive (HER2+) breast cancer is resistant to monoclonal antibody (herceptin) treatment. There are currently only three basal/HER2+ breast cancer cell lines...
Source: Cancer Cell International - Category: Cancer & Oncology Authors: Tags: Primary research Source Type: research
SummaryIn the areas of chemotherapy, targeted therapy and immunotherapy, several interesting and clinically relevant data were presented at the 2017 San Antonio Breast Cancer Symposium (SABCS). This short review focuses on dose-dense and/or sequential administration of adjuvant chemotherapy, provides an update on targeted therapies for HER2-positive and triple-negative breast cancer and summarizes new results in the field of immunotherapy.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
AbstractOverexpression of human epidermal growth factor receptor 2 (HER2) protein in association withHER2 gene amplification is found in 7 –34% of gastric cancers. In breast cancer, HER2 overexpression is a prognostic factor in advanced cases and is associated with tumor progression in ductal carcinoma in situ. However, the biological and clinical significance of HER2 status in early gastric cancer is unknown. Here, we aimed to exami ne the correlation betweenHER2 gene amplification and tumor progression in early gastric cancer. The HER2 status was evaluated in 149 lesions from 141 consecutive patients with early gas...
Source: Virchows Archiv - Category: Pathology Source Type: research
More News: Baylor College of Medicine | Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Conferences | Health | HER2 | Immunotherapy | Science | Study | Texas University | Women